Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Amortization - Intangibles (2017 - 2025)

Ptc Therapeutics has reported Amortization - Intangibles over the past 9 years, most recently at $9.3 million for Q4 2025.

  • Quarterly results put Amortization - Intangibles at $9.3 million for Q4 2025, up 182.7% from a year ago — trailing twelve months through Dec 2025 was $24.7 million (down 59.26% YoY), and the annual figure for FY2025 was $24.7 million, down 59.26%.
  • Amortization - Intangibles for Q4 2025 was $9.3 million at Ptc Therapeutics, up from $7.5 million in the prior quarter.
  • Over the last five years, Amortization - Intangibles for PTCT hit a ceiling of $77.2 million in Q4 2023 and a floor of $2.9 million in Q2 2024.
  • Median Amortization - Intangibles over the past 5 years was $15.4 million (2021), compared with a mean of $24.0 million.
  • Biggest five-year swings in Amortization - Intangibles: crashed 95.71% in 2024 and later surged 182.7% in 2025.
  • Ptc Therapeutics' Amortization - Intangibles stood at $16.3 million in 2021, then soared by 119.16% to $35.8 million in 2022, then skyrocketed by 115.51% to $77.2 million in 2023, then crashed by 95.71% to $3.3 million in 2024, then soared by 182.7% to $9.3 million in 2025.
  • The last three reported values for Amortization - Intangibles were $9.3 million (Q4 2025), $7.5 million (Q3 2025), and $4.1 million (Q2 2025) per Business Quant data.